Immune checkpoint inhibitors: a new frontier in bladder cancer.
World J Urol
; 34(1): 49-55, 2016 Jan.
Article
em En
| MEDLINE
| ID: mdl-26487055
Immunotherapy is rapidly changing the field of urologic oncology. In this review, we discuss the role of the immune system in general and place a particular emphasis on the biology of the immune checkpoint and its role in cancer. Bladder cancer, as one of the most immunogenic neoplasms, is an exciting target for immune checkpoint inhibition. Early preclinical data and human trial experience suggest that this new drug class may shape bladder cancer therapy for years to come.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Bexiga Urinária
/
Carcinoma de Células de Transição
/
Anticorpos Monoclonais Humanizados
/
Anticorpos Monoclonais
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article